X0306 4 2016-02-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001610876 Chodakewitz Jeffrey C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP GMDA, CMO Common Stock 2016-02-02 4 A 0 14416 0.01 A 114978 D Common Stock 2016-02-02 4 S 0 1100 90.89 D 113878 D Common Stock 2016-02-02 4 S 0 1275 91.80 D 112603 D Common Stock 91.05 2016-02-02 4 A 0 28735 0.00 A 2026-02-01 Common Stock 28735 28735 D Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $90.89 (range $90.49 to $91.33). Open market sales reported on this line occurred at a weighted average price of $91.80 (range $91.56 to $92.36). The option vests in 16 quarterly installments from 02/02/2016. Omar White, Attorney-In-Fact 2016-02-04